Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 32Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasm Metastasis 3Carcinoma, Ovarian Epithelial 3Pancreatic Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Sarcoma 1Recurrent Uterine Corpus Sarcoma 1Recurrence 1Pain 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Endometrial Adenocarcinoma 1

Interventions

ixabepilone 1Paclitaxel 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Malignancies × ixabepilone × Clear all
NCT00162136 2020-11-02

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

R-Pharm

Phase 1 Completed
35 enrolled 17 charts

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡